Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.


NDAQ:ALDX - Post by User

Aldeyra Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Jul 19, 2022 8:21am
133 Views
Post# 34833736

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?
$ALDX 
 
Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive results from the Phase 3 tranquility trial. The Company is scheduled to meet the FDA for a Type B Pre-NDA meeting in Q3, 2022, with a potential NDA submission likely to follow.
 
 
https://www.aviseanalytics.com/will-aldeyra-hit-the-bulls-eye-in-dry-eye/
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities